UPPSALA, Sweden, Feb. 03, 2005 (PRIMEZONE) --
Friday, February 11, 10:30 a.m, (CET) at Operaterrassen, Stockholm.
Bengt Agerup, CEO and Erika Kjellberg Eriksson, CFO, will present the company and comment on the report.
Moderator: Susanna Urdmark, Handelsbanken Capital Markets
To participate, please register in one of the following ways: at www.financialhearings.com or by phone + 46(0) 8 411 43 80.
Friday's presentation can also be followed live by telephone conference, which is accessible by dialling + 46 (0) 8 598 062 47. The slide presentation will be available at: www.q-med.com, on Friday, February 11 at 10.00 a.m.
Q-Med's year-end report will be published around 08:30 a.m Friday, February 11.
Financial information from Q-Med during Year 2005:
28 April Interim Report January -- March 2005 28 April Annual General Meeting 21 July Interim Report January -- June 2005 27 October Interim Report January - September 2005
Queries should be addressed to: Anne Rhenman Director Investor Relations & Corporate Communications Ph: +46 (0) 70 974 90 15
Note: Q-Med AB operates under the name of Q-Med Scandinavia, Inc. in the USA.
Q-Med is a rapidly growing and profitable biotechnology/medical device company that develops, produces, markets and sells medical implants. All products are based on the company's patented NASHA technology - Non-Animal Stabilized Hyaluronic Acid. The products covered by the RESTYLANE trademark are used for the filling out of lips and facial wrinkles and for facial contouring and today account for the majority of sales. RESTYLANE is sold in over 70 countries and has been approved in the USA. DUROLANE, Q-Med's product for the treatment of osteoarthritis of the hip and knee joints, has been approved in Europe since May 2001. DEFLUX is a product which has been approved in Europe and the USA for the treatment of vesicoureteral reflux (malformation of the urinary bladder) in children. ZUIDEX for the treatment of stress urinary incontinence in women has been sold in Europe since July 2002. Q-Med today has 540 employees, with approximately 350 at the company's production facility and head office in Uppsala. The Q-Med share is listed on the O- list of the Stockholm Stock Exchange, Attract 40.
This information was brought to you by Waymaker http://www.waymaker.net
The following files are available for download:
http://wpy.waymaker.net/client/waymaker1/WOLReleaseFile.aspx?id=69178&fn=wkr0010.pdf
-0-